IndustryCompany release

Ligand lifts 2026 EPS guidance as royalty revenue rises 51% to $70.3m in Q3

🇺🇸 Ligand Pharmaceuticals Inc (LGND) · Thu 29 Oct 2026

The royalty-focused biopharma company reported a GAAP net loss of $28.5m for the quarter and raised adjusted diluted earnings guidance, while reaffirming its revenue outlook.

Ligand Pharmaceuticals reported third-quarter 2026 results on 29 October, with royalty revenue up 51% to $70.3m. The company attributed the growth to the royalty portfolio it acquired from XOMA and to products including Filspari and Ohtuvayre.

Total revenues fell 32% to $78.7m. The decline was measured against the prior-year quarter, which included a gain from the divestiture of Pelthos. Ligand recorded a GAAP net loss of $28.5m for the period.

The company raised its 2026 adjusted diluted earnings per share guidance to a range of $9.50 to $9.75. It reaffirmed its existing revenue guidance, which the summary of the announcement does not detail.

Ligand also noted a royalty interest in Santen's Ryjunea and a structured financing arrangement with AvenCell. Further terms of either deal were not available in the material reviewed.

What it means for your team

  • Royalty income tied to marketed products such as Filspari and Ohtuvayre means their commercial performance and market access directly affect Ligand's reported revenue.
  • Teams working with royalty-holding partners should expect such companies to track sales, label and reimbursement developments closely, as these drive royalty streams.
  • The Ryjunea royalty interest and AvenCell financing show Ligand continuing to add to its portfolio through royalty and structured finance deals.

Company's press release (SEC filing): Ligand Pharmaceuticals Inc ↗

Article written by VigiEye from the official source (Ligand Pharmaceuticals Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →